Test Id : ABYSR
Antibody Screen with Reflexed Antibody Identification, Blood
Useful For
Suggests clinical disorders or settings where the test may be helpful
Detection of allo- or autoantibodies directed against red blood cell antigens in the settings of pretransfusion testing
Evaluation of transfusion reactions
Evaluation of hemolytic anemia
Reflex Tests
Lists tests that may or may not be performed, at an additional charge, depending on the result and interpretation of the initial tests.
| Test Id | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| ABIDR | Antibody Identification, RBC | Yes | No |
| ABTIR | Antibody Titer, RBC | Yes | No |
Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.
If the antibody screen is positive, then antibody identification will be performed.
If the patient has a history of antibodies that are still detected, the antibody screen will be canceled and replaced by the antibody identification.
If certain antibodies are detected and the patient is known to be pregnant, an antibody titration will be performed.
Method Name
A short description of the method used to perform the test
Hemagglutination
NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.
Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test
Aliases
Lists additional common names for a test, as an aid in searching
ABYSR
Antibody Screen, RBC
Antibody Screen (OB patients)
Indirect Antiglobulin Test
Indirect Coombs
Red Cell Antibody Screen
Type and Screen-Order Test TASR
Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.
If the antibody screen is positive, then antibody identification will be performed.
If the patient has a history of antibodies that are still detected, the antibody screen will be canceled and replaced by the antibody identification.
If certain antibodies are detected and the patient is known to be pregnant, an antibody titration will be performed.
Specimen Type
Describes the specimen type validated for testing
Whole Blood EDTA
Shipping Instructions
Specimen must arrive within 72 hours of collection.
Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing
Container/Tube: Pink top (EDTA)
Specimen Volume: 6 mL
Collection Instructions: Send whole blood specimen in original tube. Do not aliquot.
Forms
If not ordering electronically, complete, print, and send a Benign Hematology Test Request Form (T755) with the specimen.
Specimen Minimum Volume
Defines the amount of sample necessary to provide a clinically relevant result as determined by the testing laboratory. The minimum volume is sufficient for one attempt at testing.
3 mL
Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected
| Gross hemolysis | Reject |
Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Whole Blood EDTA | Refrigerated (preferred) | 4 days | |
| Ambient | 4 days |
Useful For
Suggests clinical disorders or settings where the test may be helpful
Detection of allo- or autoantibodies directed against red blood cell antigens in the settings of pretransfusion testing
Evaluation of transfusion reactions
Evaluation of hemolytic anemia
Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.
If the antibody screen is positive, then antibody identification will be performed.
If the patient has a history of antibodies that are still detected, the antibody screen will be canceled and replaced by the antibody identification.
If certain antibodies are detected and the patient is known to be pregnant, an antibody titration will be performed.
Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
Transfusion and pregnancy are the primary means of sensitization to red cell antigens. In a given population, 2% to 4% of the general population possess irregular red cell alloantibodies. Such antibodies may cause hemolytic disease of the newborn or hemolysis of transfused donor red blood cells.
Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
Negative
If positive, antibody identification will be performed.
Interpretation
Provides information to assist in interpretation of the test results
A positive result (antibody detected) necessitates antibody identification to establish the specificity and clinical significance of the antibody detected.
Alloantibodies detected on pregnant Mayo Clinic-Rochester patients will be evaluated for the allo-antibody titer. If antibody reacts strongly, the titre test will be performed.
Negative results indicate no antibody was detected.
Cautions
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
Clinical evaluation of antibodies identified is necessary to determine their potential for harm to the patient at this time and to assess appropriate action to be taken in the future.
Clinical Reference
Recommendations for in-depth reading of a clinical nature
Cohn CS, Delaney M, Johnson ST, Katz LM, Schwartz J, eds. Technical Manual. 21st ed. AABB; 2023
Method Description
Describes how the test is performed and provides a method-specific reference
Three type O erythrocytes with known expression of common antigenic determinants are utilized. Serum containing antibodies directed against these antigens will cause agglutination or hemolysis of the test cells. Antiglobulin phases of testing provide optimal conditions for detection of most clinically significant antibodies. If the antibody screen is positive, then antibody identification is performed.(Cohn CS, Delaney M, Johnson ST, Katz LM, Schwartz J, eds. Technical Manual. 21st ed. AABB; 2023)
PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information
Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.
Monday through Sunday
Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.
Specimen Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded
Performing Laboratory Location
Indicates the location of the laboratory that performs the test
Fees :
Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.
- Authorized users can sign in to Test Prices for detailed fee information.
- Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact Customer Service.
Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.
CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.
CPT codes are provided by the performing laboratory.
CPT codes are provided by the performing laboratory.
86850
LOINC® Information
Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the order and results codes of this test. LOINC values are provided by the performing laboratory.
| Test Id | Test Order Name | Order LOINC Value |
|---|---|---|
| ABYSR | Antibody Screen, RBC | 101678-1 |
| Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
|---|---|---|
| ABYSR | Antibody Screen, RBC | 890-4 |